1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
MPX International Corporation

MPX International Corporation

MPXI.CN
MPX International CorporationCA flagCanadian Securities Exchange
0.01
CAD
- -
- -
721,615.00Market Cap
MPX International Corporation
MPXI.CN
(Canadian Securities Exchange)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
TTM
FRC
- -
0.02
0.02
0.05
0.05
Revenue per Share
-0.05
-0.13
-0.29
-0.19
-0.2
Basic EPS, GAAP
-0.11
-0.21
-0.12
-0.09
-0.14
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
0.79
0.13
-0.05
-0.12
Book Value per Share
0.07
0.35
0.01
0.02
-0.06
Tangible Book Value per Share
45
72
140
143
144
Basic Weighted Avg Shares
- -
2
3
7
7
Sales/Revenue/Turnover
-3,234.78
-399.68
-505.51
-194.68
-244.63
Operating Margin (%)
1
3
5
6
7
Depreciation Expense
-2
-9
-41
-27
-28
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-3,266.35
-589.27
-1,294.2
-369.38
-423.71
Profit Margin (%)
- -
23
-1
-2
-10
Working Capital
1
1
9
12
17
LT Debt
26
69
34
23
10
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-33.02
-108.85
- -
-154.29
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'21
Dec'22
Mar'22
ST Debt
7
7
8
LT Borrowings
7
9
14
LT Finance Leases
4
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
144
144
144
Market Capitalization
11
4
4

Working Capital

FRC

•

in mil. unless spec.
Sep'21
Dec'22
Mar'22
Total Current Assets
13
10
8
Cash, Cash Equivalents & STI
6
4
1
Accounts Receivable, Net
1
1
1
Inventories
3
4
4
Total Current Liabilities
15
15
18
Payables & Accruals
8
8
10
ST Debt
7
7
8
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-32.85%
Free Cash Flow
- -
- -
-18.48%
Net Income, GAAP
- -
- -
-35.11%
Sales/Revenue/Turnover
- -
- -
127.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
1
1
1
1
3
2021
2
2
2
1
7
2022
2
2
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.03
-0.02
-0.04
- -
-0.29
2021
-0.02
-0.06
-0.01
- -
-0.19
2022
-0.03
-0.06
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ)
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (300534.SZ)
DMK Pharmaceuticals Corporation (0A4X.L)
BPH Global Ltd (BP8.AX)
Gabather AB (publ) (GABA.ST)
Asia Green Biotechnology Corp. (ASIA.CN)
Business
MPX International Corporation is a multinational diversified biopharmaceutical company specializing in the international cannabis industry, with core operations in cultivation, extraction, distillation, nano emulsion technology, product formulation, and marketing of cannabinoid-based medicinal and consumer products. The company’s product portfolio includes medical and adult-use cannabis flower, oils, concentrates, edibles, and wellness products delivered under proprietary brands. MPX operates across four continents with active business segments in Canada, Europe/Africa, and Asia-Pacific, maintaining licensed production facilities and retail operations in countries including Canada, Germany, South Africa, Malta, and Australia. Founded in 2015 and headquartered in Toronto, Canada, MPX also offers patient counseling and education services alongside its product sales. Recent major developments include the acquisition and refurbishment of a GMP-ready pharmaceutical manufacturing facility in Malta through its subsidiary MPXI Malta Property Ltd, enabling the production of EU-GMP quality cannabis oils and derivatives for regulated medical cannabis markets in Europe and North Africa. Strategic partnerships with local entities such as the Bortex Group support operational oversight and local distribution. MPX also continues to expand its brand presence and product offerings globally through evolving partnerships and distribution agreements in new jurisdictions. The company remains focused on innovation, including advanced extraction and formulation technologies, to enhance product quality and market reach.